Embed Size (px)
Citation preview
IN ASSOCIATION WITH
PharmaTechnology Focus
Issue 1 May 2011Drug Discovery & Development
Collaborative ActionIn this issue:
Cannabinoids rise above the stigma
The future is digital for clinical trials
Intelligent robots revolutionise lab work
Why open innovation is the way forward in the development of ever more complex drugs
Issue #1 May 2011
Contents
Drug
Dis
cove
ry a
nd D
evel
opm
ent Pharma
Technology Focus
IN ASSOCIATION WITH
Open the Treasure ChestWhy open innovation is key to the development of ever more complex drugs
BBMRI: The Industry PerspectiveHow big pharma is getting involved in a project that could revolutionise medical research
Hope on the Horizon?Treatment for HIV / Aids is more sophisticated than ever - we look at recent developments
The Rise of Cannabinoid MedicineCompounds found in the cannabis plant could herald a new wave of medical breakthroughs
Finding Focus with Clinical ITWe look at digital solutions that can help make clinical trials quicker and more cost-effective
Evolution of the Robot ScientistIntelligent robots are helping to speed up lab experiments and screening processes
IN ASSOCIATION WITH
PharmaTechnology Focus
Issue 1 May 2011Drug Discovery & Development
Collaborative ActionIn this issue:
Cannabinoids rise above the stigma
The future is digital for clinical trials
Intelligent robots revolutionise lab work
Why open innovation is the way forward in the development of ever more complex drugs
IN ASSOCIATION WITH
PharmaTechnology Focus
Issue 1 May 2011Drug Discovery & Development
Collaborative ActionIn this issue:
Cannabinoids rise above the stigma
The future is digital for clinical trials
Intelligent robots revolutionise lab work
Why open innovation is the way forward in the development of ever more complex drugs
www.ika.com
Integrated Safety in the Labguaranteed by IKA®
The add-on “safety control” says it all: the magnetic
stirrer RCT basic by IKA® offers an even higher level
of safety for lab workers. The heating plate has two
independent safety control circuits to assist users
with precise temperature control and automatic
shut off. Users can also independently adjust the
safety and medium temperature. Depending on
the application, the device can even be configured
for various heating times while offering maximum
security. The safety-relevant parts are continuously
checked throughout the operation. Self-monitoring
of all safety relevant components guarantees safety
in the event of a malfunction. By setting the inde-
pendent safety circuit we ensure that the flashpoint
of the medium will not be overshot and that ac-
cidental changes of the safety temperature are pre-
vented.
In addition, the already powerful magnetic stirrer
now has an even stronger motor. This way, a larger
speed range can be regulated. Another new feature
is an additional temperature mode for quicker heat-
ing of media. The set temperature is reached quickly
and held stable. The temperature set/actual as well
as speed set/actual are easily read due to the large
digital display. The RCT basic safety control with its
chemically resistant and fully enclosed housing in
compliance with IP 42 has been checked according
to international lab equipment standards DIN EN
IEC 61010-1, DIN EN IEC 61010-2-010, DIN EN IEC
61010-2-051 - tested and certified by cULus Inter-
national - as well as DIN EN IEC 61326-1.
The IKA® RCT basic fulfills, in all areas, the required
safety regulations for laboratory equipment. Of
course all of our products conform to CE certifi-
cation. When it comes to IKA®’s magnetic stirrer,
safety is ensured through continuous innovation
and design. IKA® continues to develop and release
products that are “designed to work perfectly” and
designed to work safety.
To read more about this product, click here
The magnetic stirrer RCT basic safety control sets new standards
About IKA®
The IKA® group is the worldwide leader in laboratory,
analytical and process technology. The laboratory and
analytical technology product line-up is comprised of
magnetic stirrers, overhead stirrers, dispersers, shak-
ers, mills, rotary evaporators, calorimeters, laboratory
reactors and incubator shakers. The process technology
department develops and distributes solutions for stir-
ring, mixing and kneading applications. The company’s
headquarters is in Staufen im Breisgau, South of Ger-
many. As a global player, IKA® has subsidiaries in the
United States of America, China, India, Malaysia and
Japan. In 2009, the owner-managed company with its
617 employees generated 67 million Euros in revenue.
Founded in 1910, IKA® now proudly looks back on
100 years of company history.
Issue #1 May 2011
Contents
Drug
Dis
cove
ry a
nd D
evel
opm
ent Pharma
Technology Focus
Open the Treasure ChestWhy open innovation is key to the development of ever more complex drugs
BBMRI: The Industry PerspectiveHow big pharma is getting involved in a project that could revolutionise medical research
Hope on the Horizon?Treatment for HIV / Aids is more sophisticated than ever - we look at recent developments
The Rise of Cannabinoid MedicineCompounds found in the cannabis plant could herald a new wave of medical breakthroughs
Finding Focus with Clinical ITWe look at digital solutions that can help make clinical trials quicker and more cost-effective
Evolution of the Robot ScientistIntelligent robots are helping to speed up lab experiments and screening processes
IN ASSOCIATION WITH
A centralised technology solution providing transparency throughout the management, reporting and analysis of all drug development data
ICON’s Integrated Technology Solution
For further information or to arrange a free consultation
Contact us
Provides true data transparency and visualisation of data from site selection through to database lock
Easy access to study trends to enable sponsors to proactively identify issues
Secure, web-based, near real-time access anytime, anywhere
Critical and more timely safety and efficacy information
End to end audit trail with chain of custody in clinical data
Scalable and leverages existing data systems
Industry News
Navigation:Select a news category to the leftClick on the headlines to read the full stories
www.ika.com
Integrated Safety in the Labguaranteed by IKA®
The add-on “safety control” says it all: the magnetic
stirrer RCT basic by IKA® offers an even higher level
of safety for lab workers. The heating plate has two
independent safety control circuits to assist users
with precise temperature control and automatic
shut off. Users can also independently adjust the
safety and medium temperature. Depending on
the application, the device can even be configured
for various heating times while offering maximum
security. The safety-relevant parts are continuously
checked throughout the operation. Self-monitoring
of all safety relevant components guarantees safety
in the event of a malfunction. By setting the inde-
pendent safety circuit we ensure that the flashpoint
of the medium will not be overshot and that ac-
cidental changes of the safety temperature are pre-
vented.
In addition, the already powerful magnetic stirrer
now has an even stronger motor. This way, a larger
speed range can be regulated. Another new feature
is an additional temperature mode for quicker heat-
ing of media. The set temperature is reached quickly
and held stable. The temperature set/actual as well
as speed set/actual are easily read due to the large
digital display. The RCT basic safety control with its
chemically resistant and fully enclosed housing in
compliance with IP 42 has been checked according
to international lab equipment standards DIN EN
IEC 61010-1, DIN EN IEC 61010-2-010, DIN EN IEC
61010-2-051 - tested and certified by cULus Inter-
national - as well as DIN EN IEC 61326-1.
The IKA® RCT basic fulfills, in all areas, the required
safety regulations for laboratory equipment. Of
course all of our products conform to CE certifi-
cation. When it comes to IKA®’s magnetic stirrer,
safety is ensured through continuous innovation
and design. IKA® continues to develop and release
products that are “designed to work perfectly” and
designed to work safety.
To read more about this product, click here
The magnetic stirrer RCT basic safety control sets new standards
About IKA®
The IKA® group is the worldwide leader in laboratory,
analytical and process technology. The laboratory and
analytical technology product line-up is comprised of
magnetic stirrers, overhead stirrers, dispersers, shak-
ers, mills, rotary evaporators, calorimeters, laboratory
reactors and incubator shakers. The process technology
department develops and distributes solutions for stir-
ring, mixing and kneading applications. The company’s
headquarters is in Staufen im Breisgau, South of Ger-
many. As a global player, IKA® has subsidiaries in the
United States of America, China, India, Malaysia and
Japan. In 2009, the owner-managed company with its
617 employees generated 67 million Euros in revenue.
Founded in 1910, IKA® now proudly looks back on
100 years of company history.
OPEN THE
CONFRONTED WITH INCREASINGLY CHALLENGING CLINICAL AND MEDICAL PROBLEMS, THEPHARMACEUTICAL INDUSTRY IS FACING HUGE PRESSURE TO DEVELOP MORE COMPLEX DRUGS. BUT NO ORGANISATION IS CAPABLE OF DOING THIS ON ITS OWN. DR PAUL STOFFELS OF JOHNSON & JOHNSON TELLS ELLY EARLS WHY OPEN INNOVATION – THE COLLABORATION BETWEEN BIG PHARMA, BIOTECH AND ACADEMIC INSTITUTIONS – IS THE WAY FORWARD
TREASURE CHEST
YOU CANNOT LIVE IN A WORLD WHERE COMPANIES THINK THEY CAN DO ALL INNOVATION IN THEIR OWN LABORATORIES ”
The simple diseases have been solved,” says Dr Paul Stoffels, worldwide chairman of pharma-ceuticals at Johnson & Johnson. “Today we are confronted with very challenging clinical and medical problems that require a significant amount of science and technology to come together to reach a solution.”
Consequently, the process of creating a new product and getting it to market has become too difficult for one organisation to undertake effec-tively alone. “Take the history and the number of products approved over the last 20 years and the amount of money invested in these products and you come to realise the numbers are staggering,” says Stoffels, who has over 15 years’ global experience in pharmaceutical and HIV/AIDS R&D.
Add to this a stringent regulatory climate and an environment in which consumers want to pay less for drugs and healthcare, and it is little wonder that the pharmaceutical industry and the scientific community are beginning to embrace a new paradigm – open innovation.
“There is a tremendous amount of science ongoing globally, and it’s difficult to work with the idea that everything can be done in one organisation,” says Stoffels. “You need so much disparate science and technology to come together to create a new solution for diseases such as Alzheimer’s, so you cannot live in a world where companies think they can do all innovation in their own laboratories.”
For Stoffels, it is essential for big pharma to access different parts of the scientific community, such as academic institutions and biotech companies, that may bring part of the solution to the table.
“I am a believer that the combination between academic science, biotech and big pharma will yield significant transformational solutions in the future for significant global problems,” he says. That is not to say that the pharmaceutical compa-nies’ labs are without merit. “They are very impor-tant because they have what is required to turn information and science into a product, into a pill, into an injection, into an antibody that gives the desired effect in the patient,” Stoffels explains.
“
www.gsk.com
We have a challenging and inspiring mission: To improve the quality of human life by enabling people to do more, feel better and live longer. This mission gives us the purpose to develop innovative medicines and products that help millions of patients and consumers around the world.
BBMRI:The IndustryPerspectiveThe Biobanking and Biomolecular Resources Research Infrastructure is paving the way for research cooperation in Europe. We talk to Dr David Cox, senior vice-president at Pfizer, to find out how big pharma is getting involved in a project that could revolutionise medical research
PHARMACEUTICAL R&D
...IT'S REALLY ALL ABOUT
DOCUMENTATION.
LEADING PROVIDER OF SOFTWARE SOLUTIONS
FOR PHARMACEUTICAL INDUSTRY
HANDLE ALL YOUR R&D PROCESSES
PLANNING
FORMULATION DEVELOPMENT
PILOT DEVELOPMENT
MANUFACTURING PROCEDURE
PROCESS VALIDATION
BATCH RECORDS
PACKAGING MATERIALS
LABELLING
STABILITY TESTING
PROJECT MANAGEMENT
WITH INFOTEHNA R&DExpertTM
JOIN US
XIII. PHARMACEUTICAL CONFERENCE
25 WED
MAY
26 THU
MAY
Woerthersee/Klagenfurt, AUSTRIA
HOPETreatment for HIV / Aids is more sophisticated than ever, but how much closer are we to finding a cure?
Chris Lo investigates the colossal challenges for organisations trying to treat, prevent, and eventually
find a cure for the world’s most feared virus
on the Horizon?
Solid doseGranulation & drying,
including spray granulation
Coating
OEB 5 (Occupational
Exposure Band 5)
high potency drugs capability
Blister and bottle packaging
LiquidsOral, topical liquids, creams
and ointments
Suspensions and solutions
Capability for handling of
flammable liquids
500l to 8000l batch sizes
CIP (Clean in Place)
Blow-Fill SealAseptic filling into PE vials
Bottlepack capabilities for
0,4 to 5ml fill volume
Vacuum leak detection
Foil wrapping
(incl. nitrogen gassing)
ServicesSmall scale equipment for
trials and formulation
Clinical study supply of products
Transfer and development
of analytical methods
ICH stability studies
EU testing & release
Cold store products
Pack optimisation
Our Competencies in Contract Manufacturingaspen bad oldesloe gmbh
industriestrasse 32-36
23843 bad oldesloe · germany
fon: +49 (0) 4531 8940-2212
fax: +49 (0) 4531 8940-92212
finn-marco scholz
business development
www.aspenbadoldesloe.com
The Rise of Cannabinoid
Medicine
A group of compounds found in the cannabis plant could herald a new wave of medical breakthroughs. Chris Lo talks to GW Pharmaceuticals executive chairman Dr Geoffrey Guy about their new cannabis-derived drug Sativex and the future for cannabinoid research
Cannabinoids, the class of chemical compounds found in the cannabis plant, could be a drug development treasure trove. They have been shown to have pain-relieving, anti-spasmodic, anti-cancer and anti- inflammatory properties. These com-pounds can be used to stimulate or suppress appetite, reduce nausea or even as an antioxidant. Their useful-ness for certain sufferers of multiple sclerosis (MS), Aids and cancer patients undergoing chemotherapy, among others, is beyond doubt. Despite the inherent pharmacologi-cal value of these substances, they have not been as intensely inves-tigated as one might suspect. The reason might be a lingering stigma surrounding cannabinoids and their perceived association with a recreational drug that is illegal in most countries.
THC, the most well-known of the cannabinoids – and the only one with a psychoactive or ‘high-
inducing’ effect – is only one of a large number of pharmacologically active cannabinoids, but its cover-age has far outstripped that of any other. Synthetic medicines that mimic the effects of cannabinoids, such as Marinol and Cesamet, are available in some countries, but there is only one licensed prescrip-tion medicine derived directly from the cannabis plant.
The world’s first cannabis-derived medicine
Sativex is an oral spray derived from THC and cannabidiol (CBD), devel-oped by UK-based pharmaceutical company GW Pharmaceuticals. The spray is fully licensed in the UK, Spain, Canada and New Zealand for the treatment of muscle spasticity in MS patients. It is also approved in Canada for the reduction of cancer pain and neuropathic pain, and is in various stages of the approval process in the European Union and in the US.
For Dr Geoffrey Guy, executive chairman at GW Pharmaceuticals, the main aim was to create a drug with the widest possible ‘therapeutic window’ – the dosage range at which a drug is effective without causing unacceptable side effects. This was achieved in the delivery method and in the combination of cannabinoids used.
The oral spray delivery allows for a more gentle absorption rate, thus maximising the tolerability of the drug and increasing the therapeutic window. “If people were to inhale THC-containing materials, their blood levels would rise to 100ng-150ng/ml in six to eight minutes,” says Guy. “With a standard 10mg four spray dose of THC by Sativex, you would find that the levels rise to about 3ng or 4ng/ml in two hours.”
According to Guy, the CBD in Sativex also plays a part in tempering the psychoactive effects of THC, making the THC more tolerable.
Another misconception is the overwhelming media focus on the cannabinoid THC, which Guy puts down to the ‘frisson’ of it being the psychoactive component of street cannabis. Indeed, recreational cannabis has been specifically bred to maximise THC at the expense of other cannabinoids. But in terms of research for future applications, Guy describes THC as the least interest-ing cannabinoid. It is when we take a look at the lesser-known cannabi-noids that this research world really begins to open up.
In basic scientific terms, cannabi-noids are chemical compounds that interact with and stimulate the cannabinoid receptors that exist in almost all living beings. These recep-tors in the body are responsible for modulating other systems in the body. The key is that cannabinoid receptors encourage homeostasis, in other words encouraging the body to do what it is supposed to do.
Unlike with synthetic medicines, which simply trigger a predeter-mined effect based on the dosage provided, the activation of a can-nabinoid receptor on two different occasions could have the opposite result, because the cannabinoid system will react in a way that most supports homeostasis.
“That again opens the therapeutic window,” he says. “It is the essential underlying strategy for developing Sativex to provide a medicine that captured the pharmacology and therapeutic benefits that were avail-able within cannabis compositions, but to remove the unwanted side effects that would be produced by inappropriate root administration of very high amounts.”
Overcoming misconceptions
With Sativex gaining approval, the concept of cannabinoid medicine has been established as more than a kooky herbal remedy. But there are still hurdles that need to be overcome in terms of acceptance.
As the head of one of the world’s leading cannabinoid research groups, one of Guy’s tasks is to debunk the myths and preconcep-tions about this emerging area of science. He explains the challenge: “We have to take more care to provide far more fundamental data than if we’d just invented a molecule and said, ‘This is what it does, please accept it’. There is an educa-tion process. And it’s very different throughout the world. We’ve been operating around the world for 12 years and each country has a very different view on it.”
This means that cannabinoids share a very good organoleptic and toxic safety profile. But the pharmacol-ogy of each cannabinoid differs in the effect that it might bring about. For example, GW Pharmaceuticals has discovered that THCV, a can-nabinoid that is an analogue of THC, acts as to reduce excess activity of the cannabinoid receptor rather than stimulate it. THCV, along with other cannabinoids such as CBD, CBDV, CBC and CBG, is forming the bulk of the company’s current research.
A new area of science
Research into the cannabinoid system is developing a new area of scientific thought, not just on environmental substances, but on a fundamental system within the human body. Discoveries in this area could hold the key to a new wave of treatment options for patients. “A few years ago, cannabinoids were referred to as the aspirin of the 21st century,” says Guy. “We have a 20 to 25-year research programme ahead of us. I think that the real benefits of cannabinoid medicines, in terms of human physiology and human pathology, will really come into their own probably in ten to 20 years.
It is a hugely promising area, although highly complex, requiring
a massive push from the academic world and the pharmaceutical industry to develop. “We have to develop whole new types of science and new ways of assessing what might be going on when you’re in-troducing a range of cannabinoids,” Guy explains. “We and our partners are spending our time and resources to lay down a basis of not only cannabinoid science, but also a very different way of assessing how each of these new cannabinoids are going to have a benefit. So watch this space.”
Online- Moisture Measurement in Granulation and Drying
New online moisture measurement for Fluid bed dryers
Drying after granulation is one of the most important steps in the production of pharmaceutical products. Especially the target mois-ture of e.g. 2% +/-0,2% is important for the production and the qua-lity of the product. TEWS-Elektronik located in Hamburg/Germa-ny is one of the most experienced companies in using microwave technology for fast and accurate moisture measurement for online and laboratory. The latest development has been made especially to meet the requirements of the pharmaceutical industry.
Some of the key features are:
• Fast and accurate measurements of product moisture and temperature• Indication when target moisture is achieved• Measurement of core moisture of granulate not only surface like optical systems• Density independent measurement• No influence from the microwave to the product• Up to 400 measurements/sec• Meets GMP requirements• EX – certificate• Connectivity: 4-20mA, TCP/IP, Profibus, PC• Easy to refit existing systems
TEWS Elektronik GmbH & Co. KG Sperberhorst 10 . 22459 Hamburg . Germany Phone +49.40.555.911.0 . Fax +49.40.552.575.9 [email protected] www.tews-elektronik.comFor more
information visitour website:
tews-elektronik.com
47.5°C37.5°C
37.5°C
0.0
0.14
0.12
0.10
0.08
0.06
0.04
0.5 1.0 1.5 2.0 2.5 3.0 3.5
MW-Moisture
Reference-Moisture %
Calibration with temperature compensation
0101101001
LEVERAGING TECHNOLOGY TO STREAMLINE THE CLINICAL TRIAL PROCESS IS BENEFICIAL TO BIG PHARMA AND THEPATIENTS IT SERVES. CHRIS LO LOOKS INTO THE NEW DIGITAL HORIZON FOR DRUG DEVELOPMENT
TRIAL AND ERROR:
0101101101
Finding Focus with Clinical IT
01101011010
Along with the likes of expiring patents and the booming illicit trade in counterfeit medication, the difficulty of modern clinical trials can create a challenge for pharmaceutical companies and medical technology manufacturers looking to get their products to market as quickly as possible. The complexity of the international regulation system, as well as dwindling patient bases for clinical trials, is forcing the industry to look for new ways to economise the development process.
But a strict approval process is no guarantee against safety breaches and product recalls. At the beginning of February, a report by the Advanced Medical Technology Association (AdvaMed) stated that recall rates for medical devices were similar in the US and Europe, despite the former having a more drawn-out path to approval. In order to overcome these obstacles, the pharmaceutical and medical device industries must make better use of the digital revolution of the last ten years.
Better implementation of IT could hold the key to making the long process of putting a medical product into the hands of doctors and patients quicker, more cost-effective and safer. Although progress has been made by big pharma and other industry organisations, there is still more that could be done to integrate IT into the medical development world.
1011010010
Logistics &Supply Chain
PharmaTechnology Focus
EditorialDuncan West Head of Editorial and Production
[email protected] Hauner Editor / Production Manager
[email protected] Hammond Graphic and Flash Designer
[email protected] Luff Graphic and Flash Designer
SalesJasmin Keick Sales [email protected]
MarketingAshleigh Cushing Marketing Executive
[email protected] Fleet Product Coordinator
Pharma Technology Focus is a product of Net Resources International.Copyright 2011 Net Resources International, a trading division of SPG Media Limited. Registered office John Carpenter House, John Carpenter
Street, London, EC4Y 0AN, UK. Company registration number 01155599.
All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.
NET RESOURCES I N T E R N A T I O N A L
Follow us
Stay in touch
Read it firstSubscribe
The pharmaceutical industry faces unique challenges in logistics and supply chain management. Delays or disruptions do not only affect profits – they can be a matter of life and death.
Next month we look behind the scenes of the massive operation of getting the drug to the patient. We talk to industry experts about their risk management strategies and find out how companies can develop robust delivery strategies.
We also examine the growing role of IT in supply chain management and investigate how scientist and packaging experts work on new ways to overcome the limitations of pharmaceutical cold chains.
Next Issue: June 2011
www.iconplc.com
A Technology Solution for Improving the Management of Drug Development Programs
Advertorial
Kris Gustafson, Senior Vice President, Global Data and Technology Services
EVOLUTIONRobot Scientistof the
In the increasingly competitive, global and high-expense world of drug discovery and development, HTS and HCS have been a vital part of the pharmaceutical company’s armoury for some time. As the science around automation and robotics becomes ever more advanced, their importance is on the rise, as Nic Paton learns from robotics pioneer Dr Ross King
Put simplistically, high throughput screening (HTS) and high content screening (HCS) are the workhorses of the pharmaceutical industry, partic-ularly when it comes to searching for and creating new pharmaceutical compounds.
In HTS, a screening facility typically holds a library of stock plates whose contents have been cata-logued and have been created by the laboratory or supplied by a commercial source. From these stock plates separate assay plates are created by pipetting a small amount of liquid from the wells of a stock plate to the corresponding wells of a completely empty plate. Then, normally through
an automated process, the assay-microplates are transported from station to station for sample and reagent addition, mixing, incubation, and finally readout or detection.
The beauty of an HTS system is the way it can be used to prepare, incubate and analyse many plates simultaneously. This can greatly speed up the data collection process, with HTS robots often testing up to 100,000 compounds per day. The results of those tests determine the quantita-tive structure-activity relationships that relate the structure of a chemical compound to its pharmacological activity.
HCS, by comparison, uses modern cell biology, with image analysis being used to measure changes in properties of the cells caused by external treatment, such as chemical inhibitors, but also using automated high-resolution microscopy and robotic handling.
HCS is most often used as a technology to determine whether, or how, a potential drug affects aspects of cell function involved in or describing a disease. HCS has been used in drug discovery for more than a decade, with its use growing and becoming more mainstream as technology has advanced.
The Aclar® Advantage
More information: www.aclaradvantage.com© 2011 Honeywell Specialty Materials
Honeywell Aclar® Film Honeywell Aclar Film protects your product with the ultimate thermoform high barrier film. It provides operational, supply chain and sales advantages
by reducing pack sizes up to 55%. And it helps to lower costs by streamlining packaging operations and improving flexibility. Visit Aclaradvantage.com today to learn more about how Aclar can help your packaging strategy.
Logistics &Supply Chain
PharmaTechnology Focus
EditorialDuncan West Head of Editorial and Production
[email protected] Hauner Editor
[email protected] Hammond Flash Designer
[email protected] Luff Flash Designer
SalesJasmin Keick Sales [email protected]
MarketingAshleigh Cushing Marketing Executive
[email protected] Fleet Product Coordinator
Pharma Technology Focus is a product of Net Resources International.Copyright 2011 Net Resources International, a trading division of SPG Media Limited. Registered office John Carpenter House, John Carpenter
Street, London, EC4Y 0AN, UK. Company registration number 01155599.
All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.
NET RESOURCES I N T E R N A T I O N A L
Follow us
Stay in touch
Read it firstSubscribe
The pharmaceutical industry faces unique challenges in logistics and supply chain management. Delays or disruptions do not only affect profits – they can be a matter of life and death.
Next month we look behind the scenes of the massive operation of getting the drug to the patient. We talk to industry experts about their risk management strategies and find out how companies can develop robust delivery strategies.
We also examine the growing role of IT in supply chain management and investigate how scientist and packaging experts work on new ways to overcome the limitations of pharmaceutical cold chains.
Next Issue: June 2011
Gold Sponsor:
Register online now at: www.arena-international.com/clinicaldataforum/index.html
THE EUROPEAN CLINICAL DATA FORUM
COMBINING THE 11TH ANNUAL ECLINICAL TRIALS AND 4TH ANNUAL EVOLUTION OF CLINICAL DATA MANAGEMENT:
Tuesday 24 - Wednesday 25 May 2011, The Westin Grand Munich, Munich, Germany
THE one-stop shop for clinical data professionals; bringing you 2 conferences for the price of 1!
EVENT HIGHLIGHTS:Meet every delegate in our expanded audience during Speed Networking
Whether your focus is technical or strategic, you will fi nd the answers to your questions here
Compare all the data capture, eClinical and data management vendors under one roof
A platform to sit down with your peers and discuss this time of change for clinical data teams
The de� nitive meeting place for data management professionals to optimise standardisation, maximise ef� ciency of collection and anticipate the future of clinical data management
This year over 150
delegates
Attended by: Pharma,
Biotech, Regulator and
CRO
Industry renowned
guest speakers from
the USSilver Sponsors:Platinum Sponsor:
A single pass gives you access to TWO full conferences – select from the sessions across both programmes that meet your operational challenges
TOP SPEAKERS:Dirk Langeneckhardt, Head Data Management Coordination, MERCK SERONO
Michael Herschel, Director Clinical Research, GLAXOSMITHKLINE
Guenter Briegel, Business Project Manager, BOEHRINGER-INGELHEIM
Herbert Noack, Senior Project Statistician, BOEHRINGER INGELHEIM
Katalina Mettke, Senior GCP Inspector, BFARM
Tero Laulajainen, Global Head of Clinical Operations, ROCHE DIAGNOSTICS
Ramzi Najm, VP - R&D Information & Technology Management, ALLERGAN US
Anastasia Christianson, Senior Director Discovery Information, AstraZeneca
Nadir Ammour, Business and Technology Innovation Lead, SANOFI AVENTIS
THE one-stop shop for clinical data professionals; bringing you 2 conferences for the price of 1!
TAILORYOUR
AGENDA
Industry News
Navigation:Select a news category to the leftClick on the headlines to read the full stories
IN ASSOCIATION WITH
PharmaTechnology Focus
Issue 1 May 2011Drug Discovery & Development
Collaborative ActionIn this issue:
Cannabinoids rise above the stigma
The future is digital for clinical trials
Intelligent robots revolutionise lab work
Why open innovation is the way forward in the development of ever more complex drugs
PharmaTechnology Focus
Issue 1 May 2011
Drug Discovery & Development
Collaborative ActionIn this issue:
Cannabinoids rise above the stigma
The digital future of clinical trials
Intelligent robots speed up screening
Why open innovation is the way forward in the development of ever more complex drugs
IN ASSOCIATION WITH
PharmaTechnology Focus
Issue 1 May 2011
Drug Discovery & Development
Collaborative ActionIn this issue:
Cannabinoids rise above the stigma
The digital future of clinical trials
Intelligent robots speed up screening
Why open innovation is the way forward in the development of ever more complex drugs
IN ASSOCIATION WITH
IN ASSOCIATION WITH
PharmaTechnology Focus
Issue 1 May 2011Drug Discovery & Development
Collaborative ActionIn this issue:
Cannabinoids rise above the stigma
The future is digital for clinical trials
Intelligent robots speed up screening
Why open innovation is the way forward in the development of ever more complex drugs
